A long-term retrospective study of young women with essential thrombocythemia

Mayo Clinic Proceedings

Volumn 76, Issue 1, 2001, Pages 22-28

  Tefferi, Ayalew ^a   Fonseca, Rafael ^a   Pereira, Denise L ^a   Clark Hoagland, H ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ANAGRELIDE; ANTITHROMBOCYTIC AGENT; BUSULFAN; CHLORAMBUCIL; HYDROXYUREA; PHOSPHORUS;

ACUTE LEUKEMIA; ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFECT; ECTOPIC PREGNANCY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; MAJOR CLINICAL STUDY; PREGNANCY COMPLICATION; PROGNOSIS; SPONTANEOUS ABORTION; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; VEIN THROMBOSIS;

EID: 0035160530     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/76.1.22     Document Type: Article

References (39)

1. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County study, 1976-1995. Am J Hematol. 1999;61:10-15.
2. Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer. 1991;67:2658-2663.
3. Gugliotta L, Marchioli R, Fiacchini M, et al. Epidemiological, diagnostic, therapeutic and prognostic aspects of essential thrombocythemia in a retrospective study of the GIMMC group in two thousand patients [abstract]. Blood. 1997;90(suppl l):348a.
4. McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the UK. Hematol Oncol. 1997; 15:173-189.
5. Hamilton GC. Platelet count. Emerg Med Clin North Am. 1986;4: 75-85.
6. Thiele J, Zankovich R, Steinberg T, Kremer B, Fischer R, Diehl V. Primary (essential) thrombocythemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosis-a critical evaluation of clinical and histomorphological data. Acta Haematol. 1989;81:192-202.
7. Koike T, Uesugi Y, Toba K, et al. 5q-Syndrome presenting as essential thrombocythemia: myelodysplastic syndrome or chronic myeloproliferative disorders? [letter]. Leukemia. 1995;9:517-518.
8. Cervantes F, Colomer D, Vives-Corrons JL, Rozman C, Montserrat E. Chronic myeloid leukemia of thrombocythemic onset: a CML subtype with distinct hematological and molecular features? Leukemia. 1996;! 0:1241-1243.
9. Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood. 1999:93:417-424.
10. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood. 1998:91:616-622.
11. Tefferi A, Elliott MA, Solberg LA Jr, Silverstein MN. New drugs in essential thrombocythemia and polycythemia vera. Blood Rev. 1997;ll:l-7.
12. Murphy S, Peterson P, Hand H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol. 1997;34:29-39.
13. Beressi AH, Tefferi A, Silverstein MN, Petitt RM, Hoagland HC. Outcome analysis of 34 pregnancies in women with essential thrombocythemia. Arch Intern Med. 1995;155:1217-1222.
14. Lahuerta-Palacios JJ, Bornstein R, Fernandez-Debora FJ, et al. Controlled and uncontrolled thrombocytosis: its clinical role in essential thrombocythemia. Cancer. 1988:61:1207-1212.
15. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8:556-562.
16. Colombi M, Radaelli F, Zocchi L, Maiolo AT. Thrombotic and hemorrhagic complications in essential thrombocythemia: a retrospective study of 103 patients. Cancer. 1991;67:2926-2930.
17. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. A' EnglJMed. 1995:332:1132-1136.
18. Ruggeri M, Finazzi G, Tosetto A, Riva S, Rodeghiero F, Barbui T. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol. 1998; 103:772-777.
19. Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer. 1990:66:549-556.
20. Budde U, Schaefer G, Mueller N, et al. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood. 1984;64: 981-985.
21. Tefferi A, Nichols WL. Acquired von Willebrand disease: concise review of occurrence, diagnosis, pathogenesis, and treatment. Am J Med. 1997; 103:536-540.
22. Watson KV, Key N. Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors. Br J Haematol. 1993;83:198-203.
23. van Genderen PJ, Mulder PG, Waleboer M, van de Moesdijk D, Michiels JJ. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol. 1997;97:179-184.
24. Mittelman F. The Third International Workshop on Chromosomes in Leukemia. Lund, Sweden, July 21-25, 1980, introduction. Cancer Genet Cytogenet. 1981 ;4:96-98.
25. Geller SA, Shapiro E. Acute leukemia as a natural sequel to primary thrombocythemia. Am J Clin Pathol. 1982;77:353-356.
26. Shibata K, Shimamoto Y, Suga K, Sano M, Matsuzaki M, Yamaguchi M. Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation-a brief review of recent literature. Acta Haematol. 1994;91:84-88.
27. Nand S, Stock W, Godwin J, Fisher SG. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Am J Hematol. 1996;52:42-46.
28. Liozon E, Brigaudeau C, Trimoreau F, et al. Is treatment with hydroxyurea leukomogenic in patients with essential thrombocythemia? an analysis of three new cases of leukaemic transforma-tion and review of the literature. Hematol Cell Ther. 1997;39: 11-18.
29. Griesshammer M, Heimpel H, Pearson TC. Essential thrombocythemia and pregnancy. Leuk Lymphoma. 1996;22(suppl l):57-63.
30. Pagliaro P, Arrigoni L, Muggiasca ML, Poggio M, Russo V, Rossi E. Primary thrombocythemia and pregnancy: treatment and outcome in fifteen cases. Am J Hematol. 1996;53:6-10.
31. Ebert U, Loffler H, Kirch W. Cytotoxic therapy and pregnancy. PharmacolTher. 1997;74:207-220.
32. Delage R, Demers C, Cantin G, Roy J. Treatment of essential thrombocythemia during pregnancy with interferon-alpha. Obstet Gynecol. 1996;87:814-817.
33. Milano V, Gabrielli S, Rizzo N, et al. Successful treatment of essential thrombocythemia in a pregnancy with recombinant interferon-alpha 2a. J Matern Fetal Med. 1996;5:74-78.
34. Ridker PM, Miletich JP, Buring JE, et al. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med. 1998; 128:1000-1003.
35. Bucalossi A, Marotta G, Bigazzi C, Galieni P, Dispensa E. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Am J Hematol. 1996; 52:14-20.
36. Anagrelide Study Group. Anagrelide, a therapy for tnrombocythemic states: experience in 577 patients. Am J Med. 1992;92:69-76.
37. Elliott MA, Tefferi A. Interferon-alpha therapy in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 1997; 23:463-472.
38. Weinfeld A, Swolin B, Westin J. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur JHaematol. 1994;52:134-139.
39. Tefferi A, Silverstein MN. Treatment of polycythaemia vera and essential thrombocythaemia. Baillieres Clin Haematol. 1998;! 1: 769-785.